<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557191</url>
  </required_header>
  <id_info>
    <org_study_id>2015-4484</org_study_id>
    <nct_id>NCT02557191</nct_id>
  </id_info>
  <brief_title>Biomarkers, Neurodevelopment and Preterm Infants</brief_title>
  <official_title>Biomarkers to Predict Neurodevelopmental Outcomes in Very Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 2% of neonates in the US are born very preterm. Preterm births are associated
      with impaired cognitive, language and motor function, and increased risk for autism spectrum
      disorders. Epidemiological studies indicate a dose-response relationship between gestational
      age at delivery and cognitive impairments, with the most immature of newborns being the most
      susceptible to developmental delays. Sensitive and reproducible biomarkers of long-term
      neurocognitive impairments are currently lacking. The investigators seek to identify
      epigenetic markers that mediate the relationship between adverse prematurity-related
      exposures and neurocognitive impairments. The overarching hypothesis of this proposal is that
      DNA methylation profiles of CD34+ hematopoetic progenitor and stem cells from very preterm
      infants can be used as a risk-stratifying biomarker for predicting neurocognitive impairment
      in childhood.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Brain white matter development</measure>
    <time_frame>38-42 weeks adjusted age</time_frame>
    <description>Brain MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopment</measure>
    <time_frame>38-42 weeks adjusted age</time_frame>
    <description>Administration of NICU Neonatal Neurobehavioral Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopment</measure>
    <time_frame>18-24 months adjusted age</time_frame>
    <description>Administration of Bayley Scales of Infant and Toddler Development, 3rd edition</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Preterm</condition>
  <condition>Neurodevelopmental Disorder</condition>
  <condition>Epigenetic Changes</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Preterm infants &lt;32 weeks gestational age</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cord blood, buccal swab and urine samples will be collected from enrolled patients.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Preterm infants &lt;32 weeks GA
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt;32 weeksâ€Ÿ gestation

          -  Born at Weiler Division of Montefiore

        Exclusion Criteria:

          -  Intraventricular hemorrhage

          -  Chromosomal abnormalities

          -  Congenital viral conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mamta Fuloria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mamta Fuloria, MD</last_name>
    <phone>718-904-4105</phone>
    <email>mfuloria@montefiore.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jack D. Weiler Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamta Fuloria, MD</last_name>
      <phone>718-904-4105</phone>
      <email>mfuloria@montefiore.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Mamta Fuloria</investigator_full_name>
    <investigator_title>Assistant Professor, Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Neurodevelopmental Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

